Relay Therapeutics financials
$18.36+3.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $350.0K | $3.0M | $7.0M | $0.00 | $677.0K | $7.7M | $0.00 | $0.00 | $0.00 | $10.0M | — | $25.2M |
| Gross profit | $350.0K | $3.0M | $7.0M | $0.00 | $677.0K | $7.7M | $0.00 | $0.00 | $0.00 | $10.0M | — | $25.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | — | — | — | 100.0% | — | 100.0% |
| Operating income | -$90.8M | -$78.6M | -$60.6M | -$80.4M | -$76.8M | -$84.9M | -$85.0M | -$96.4M | -$100.8M | -$90.4M | — | -$73.6M |
| Net income | -$83.7M | -$73.5M | -$54.9M | -$74.1M | -$70.4M | -$76.0M | -$76.0M | -$88.1M | -$92.2M | -$81.4M | — | -$65.7M |
| Net margin | −23916.3% | −2448.8% | −784.1% | — | −10395.1% | −990.2% | — | — | — | −813.3% | — | −260.8% |
| Diluted EPS | $-0.41 | $-0.41 | $-0.32 | $-0.43 | $-0.41 | $-0.46 | $-0.45 | $-0.63 | $-0.69 | $-0.62 | — | $-0.54 |
| EBITDA | -$90.5M | -$78.1M | -$60.0M | -$79.6M | -$75.8M | -$83.7M | -$83.6M | -$95.0M | -$99.4M | -$89.0M | $0.00 | -$72.2M |
| Operating cash flow | -$54.1M | -$51.1M | -$44.9M | -$62.1M | -$55.3M | -$73.2M | -$57.9M | -$75.1M | -$65.8M | -$50.3M | -$89.2M | -$75.4M |
| Free cash flow | -$54.1M | -$51.1M | -$44.9M | -$62.1M | -$55.3M | -$73.6M | -$57.9M | -$75.3M | -$65.8M | -$52.1M | -$89.3M | -$76.0M |
| Diluted shares | 202.8M | 179.8M | 173.5M | 172.4M | 171.3M | 169.2M | 167.6M | 140.2M | 132.8M | 130.8M | 125.1M | 122.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $121.2M | $204.6M | $84.0M | $91.6M | $113.9M | $93.5M |
| Short-term investments | $789.7M | $437.5M | $470.5M | $504.9M | $542.8M | $616.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $967.5M | $699.6M | $621.3M | $670.0M | $728.8M | $799.4M |
| Total liabilities | $77.4M | $57.4M | $54.3M | $62.3M | $63.2M | $78.3M |
| Shareholders' equity | $890.0M | $642.2M | $567.1M | $607.7M | $665.7M | $721.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology